On the basis of our previous reports that cardioprotection induced by ischaemic preconditioning induces autophagy and that resveratrol, a polyphenolic antioxidant present in grapes and red wine induces preconditioning-like effects, we sought to determine if resveratrol could induce autophagy.
Introduction
As cardiac myocytes are terminally differentiated, cellular degradation via ubiquitin-proteasomal pathway and/or autophagy may play an important role in the homeostasis of cardiac cells. 1 Autophagy is a catabolic process through which cells' own components are degraded using the lysosomal machineries. In normal conditions, autophagy occurs at low levels for the turnover of damaged or long-lived proteins, macromolecules, and organelles like mitochondria, ribosomes, endoplasmic reticulum, and peroxisomes. 2 Autophagy provides a necessary source of energy for the cardiac myocytes during early neonatal starvation period. 3 However, autophagy is shown to be the main mechanism causing cell death leading to the progression from compensated hypertrophy to heart failure and left ventricular systolic dysfunction in pressure-overloaded human heart. 4, 5 Also, in dilated cardiomyopathy patients, autophagy is associated with the degradation of damaged intracellular organelles leading to the destruction of cardiomyocytes. 6 Moreover, basal level of autophagy is triggered in pressure-overloaded myocardium, a major risk factor for cardiac hypertrophy and heart failure. 7 In spite of this, autophagy is shown to protect the myocardium and cardiac cells against ischaemia -reperfusion (IR) injury, 8, 9 and recently, we have shown that ischaemic preconditioning, a state-of-the-art technique for the protection of myocardium induces cardiac autophagy. 8, 10 Recently, autophagy has been found to be regulated by redox signalling. 11, 12 As resveratrol, a polyphenolic phytoalexin found in grapes, wines, peanuts, and several other fruits and vegetables, has been found to precondition the ischaemic myocardium by redox signalling, 13 we used this compound to explore the mechanism of cardiac autophagy induced by IR. Previously, we have shown that resveratrol (3,4 ′ ,5-trihydroxy-trans-stilbene) protects the cardiovascular system by diverse mechanisms, mainly by the inhibition of apoptotic cell death at very low concentrations. 14 In another study, we found that resveratrol provides cardioprotection via redox signalling and is likely to play a role in switching IR-induced death signals into survival signals through the activation of Akt and Bcl-2. 15 Recently, resveratrol was found to induce caspase-independent cancer cell death through autophagocytosis. 16, 17 As resveratrol generates a survival signal at a relatively low concentration, we hypothesized that resveratrol might induce autophagy for the protection of myocardium against IR injury. To test this hypothesis, we examined the effects of resveratrol at different doses on the induction of the autophagy. Our results confirmed for the first time that resveratrol induces cell survival through the induction of autophagy at a low concentration both in H9c2 cardiac myoblast cells and in the rat myocardium, and the autophagy in part is mediated through the activation of mammalian target of rapamycin (mTOR)-Rictor (mTOR complex 2, mTORC2) survival pathway.
2. Methods
Animals
All animals used in this study received humane care in compliance with the regulations relating to animals and experiments involving animals and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, NIH Publication, 1996 edition, and all the protocols were approved by the Institutional Animal Care Committee of University of Connecticut Health Center, Farmington, CT, USA. Male Sprague -Dawley rats weighing between 250 and 300 g were fed ad libitum regular rat chow with free access to water until the start of the experimental procedure. Animals were gavaged with one of the three different doses of resveratrol (2.5, 25, or 100 mg/kg/day) for 10 days. Wortmannin (15 mg/kg) was injected into rats via intraperitoneal route 30 min before isolation of heart.
Cell culture
Rat myocardium-derived H9c2 cardiac myoblast cell line was in Dulbecco's Modified Eagle's Medium (Invitrogen, Grand Island, NY) containing 4 mM L-glutamine, 4.5 g/L glucose, and 10% foetal bovine serum (Invitrogen). Treatment with rapamycin (100 nM), wortmannin (2 mM), and 3-methyladenine (10 mM) were accomplished by adding these compounds 15 min before resveratrol treatment. One of the three different doses of resveratrol (0.1, 1, and 100 mM) was added 1 h before hypoxia -reoxygenation (HR). Experimental procedures are depicted in Supplementary material online, Figure S1 .
In vitro siRNA transfection
In vitro siRNA transfection of Rictor and control siRNAs (Santa Cruz Biotechnology) into H9c2 cells was performed using TransPass R2 Transfection Reagent (New England BioLabs) as described earlier. 8 
HR in cell culture
H9c2 culture plates were subjected to 30 min of hypoxia followed by 1 h of reoxygenation as mentioned in our previous study. 8 
Immunofluorescence staining in H9c2 cells
Immunofluorescence staining with LC3-II antibody followed by confocal microscopy was performed as mentioned earlier. 8 
Autophagosome assay
Labelling of autophagic vacuoles with monodansylcadaverine followed by fluorescence photometry was performed. 18 Details are given in Supplementary material online, Supplementary Method.
Cell death assay
Cell death analysis was performed with the culture medium at the end of experimentation using LDH Cytotoxicity Assay kit (Cayman Chemical Company, Ann Arbor, MI, USA) as described by the manufacturer.
Cell survival assay
Viability of cells was studied using MTT Cell Proliferation Assay kit (Cayman Chemical Company) as described by the manufacturer.
Immunoprecipitation
Cells were lysed in RIPA buffer and the total cell lysate containing 500 mg of total protein was immunoprecipitated with mTOR and Protein A Sepharose beads (Zymed, San Francisco, CA, USA) as mentioned earlier. 8 
Isolated heart preparation
Isolated working and non-working heart preparations were performed using Langendorff perfusion apparatus as mentioned earlier. 8 Functional parameters were measured at the baseline level and during the experiments. Experimental procedures are depicted in Supplementary material online, Figure S1 .
Western blot analysis
Total cell lysate from cell culture or cytosolic extract from rat heart tissue or immunoprecipitated samples were separated in SDS-PAGE and transferred to nitrocellulose filters and analysed by western blotting as mentioned earlier. 8 
Transmission electron microscopy
Small left ventricular heart tissue samples of about 1 mm 3 were fixed by immersion in 4% glutaraldehyde. Small fragments of myocardium were processed for transmission electron microscopy (TEM) according to routine procedures, as we previously described. 19, 20 2.13 Assessment of apoptotic cell death transferase dUTP nick end labelling (TUNEL) apoptotic analysis was performed using DeadEnd TM Fluorimetric TUNEL System (Promega, Madison, WI, USA) as described by the manufacturer.
Statistical analysis
All values are expressed as the mean + standard error of mean. One-way analysis of variance test followed by Bonferoni's correction was first carried out to test for any differences between the mean values of all groups. Student's t-test was performed to compare the difference between control and Rictor siRNA-treated groups in Figure 6 . The results were considered significant, if P , 0.05. N. Gurusamy et al.
Results

Resveratrol treatment induces autophagy in H9c2 cardiac cells
Thirty minutes of hypoxia followed by 1 h of reoxygenation in H9c2 cells to some extent induced autophagy ( Figure 1A) . Treatment with low doses of resveratrol (0.1 and 1 mM) followed by HR strongly induced autophagy. The induction of autophagy was confirmed by the increased protein expression of LC3-II, an autophagosomal membrane component, and the enhanced ratio of LC3-II/LC3-I ( Figure 1B) . Moreover, the markers of autophagy such as Atg5 and Beclin-1 were also enhanced in low doses of resveratrol-treated cells ( Figure 1A) . The amount of autophagic vacuole formation evaluated by staining the cells with monodansylcadaverine followed by spectrofluorometric analysis showed that autophagosome vacuoles formation was enhanced under low doses of resveratrol treatment ( Figure 1C) .
Confocal fluorescent microscopic analysis further showed that the expression of LC3-II was enhanced in low doses of resveratroltreated cells ( Figure 1D and E). However, high dose of resveratrol (100 mM) reduced the extent of autophagy ( Figure 1A -E). Treatment with rapamycin, an inhibitor of mTOR known to induce autophagy, did not significantly induce the autophagy compared with low-dose (1 mM) resveratrol alone ( Figure 1A -E). However, treatment with inhibitors of autophagy such as wortmannin and 3-methyladenine significantly inhibited the low dose (1 mM) resveratrol-induced autophagy ( Figure 1A -E).
Low doses of resveratrol-mediated autophagy enhance cell survival
When autophagy was induced with low doses of resveratrol, the cell survival as indicated by MTT cell survival assay was significantly increased than HR ( Figure 2A) . A high dose of resveratrol slightly reduced the cell survival. Pre-treatment of cells with rapamycin alone increased the cell survival compared with HR alone (data not shown); however, pre-treatment with both rapamycin followed by 1 mM resveratrol did not significantly alter the cell survival than the resveratrol alone ( Figure 2A ). When autophagy was inhibited with inhibitors of autophagy, the low-dose resveratrol-induced cell survival was attenuated ( Figure 2A ). The pre-treatment of cells with low doses resveratrol significantly reduced the cell death as indicated by the reduced lactate dehydrogenase (LDH) activity in the medium ( Figure 2B ). The LDH activity was higher with high dose of resveratrol treatment. Pre-treatment of cells with rapamycin alone decreased the LDH release than HR (data not shown); however, pre-treatment with rapamycin followed by 1 mM resveratrol did not significantly alter the LDH release compared with resveratrol alone ( Figure 2B ). Inhibition of autophagy by treatment with 3-methyladenine and wortmannin elevated the release of LDH compared with low-dose resveratrol-treated samples indicating the incidence of cell death ( Figure 2B) .
Further, HR in cardiac myoblast cells decreased the Ser 473 phosphorylation of Akt, a survival signalling kinase. Pre-treatment of cells with low doses of resveratrol followed by HR increased the activation of Akt during which the autophagy was enhanced ( Figure 2C and D) . Though dual treatment of cells with rapamycin and resveratrol did not enhance autophagy compared with low doses of resveratrol alone, the level of phosphorylation of Akt was enhanced in dualtreated cells than low-dose resveratrol-treated cells alone ( Figure 2C  and D) . Both the inhibitors of autophagy inhibited the activation of Akt ( Figure 2C and D) .
Resveratrol induces autophagy in the myocardium
In accordance with our previous study results, 14 the cardiac functional parameters like left ventricular developed pressure (LVDP), and its first derivative of LV max dp/dt and aortic flow were significantly improved during the 2 h of reperfusion period for the low-dose resveratrol (2.5 mg/kg/day) treated hearts compared with the control hearts (see Supplementary material online, Figure  S2 ). However, treatment with high dose of resveratrol (100 mg/ kg/day) and treatment with autophagic inhibitor wortmannin attenuated the low-dose resveratrol-induced improvement in the cardiac function (see Supplementary material online, Figure S2 ). Treatment of rats with resveratrol at the dose of 2.5 mg/kg/day for 10 days induced the autophagy shown by the induction of LC3-II, LC3-II/ LC3-I, and Beclin-1 ( Figure 3A and B). However, high doses of resveratrol (25 and 100 mg/kg/day) decreased the expression of LC3-II and Beclin-1 ( Figure 3A and B). Single intraperitoneal injection of wortmannin (15 mg/kg), an inhibitor of autophagy, attenuated the low-dose resveratrol (2.5 mg/kg/day)-induced autophagy ( Figure 3A and B). TEM images of the myocardium showed the presence of increased number of double membrane structured autophagosomes in low-dose resveratrol-treated animal groups ( Figure 3C and D) . The average number of autophagosomes found through TEM is positively correlated with the LC3-II protein expression in the myocardium. Though it is not statistically significant, the average number of autophagosomes per 2500 mm 2 is 28 and 15 for low-dose resveratrol and wortmannin treated samples, respectively. The 
Resveratrol-mediated autophagic induction is negatively correlated with the induction of apoptosis
Apoptosis analyses performed via terminal deoxynucleotidyl TUNEL staining indicate that the percentage of apoptotic cells was negatively correlated with the induction of autophagy in the myocardium ( Figure 4A and B) , i.e. when autophagy was highly induced as in the case of low dose of resveratrol treatment, the apoptosis was minimum. Whereas, when the autophagy was reduced as in the case of high-dose resveratrol and wortmannin-treated hearts, the percentage of apoptosis was increased ( Figure 4A and B) .
Treatment with resveratrol dose dependently inhibits mTOR complex 1
The protein kinase mTOR plays an essential role in sensing and responding to nutrients, stress, and intracellular energy state. mTOR signalling negatively regulates autophagy, i.e. the phosphorylation and activation of mTOR is inhibited when autophagy is induced.
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HR in cardiac myoblast cells induced the phosphorylation of mTOR at both serine 2448 and serine 2481 sites ( Figure 5A -C) . Under resveratrol treatment, mTOR was differentially regulated, i.e. phosphorylation of mTOR at serine 2448 was inhibited, whereas the phosphorylation of mTOR at serine 2481 was increased, and it was attenuated with the high-dose resveratrol ( Figure 5A -C ) . As expected, treatment with rapamycin alone (data not shown) or along with resveratrol treatment inhibited the activation of mTOR phosphorylation at both serine 2448 and serine 2481 sites ( Figure 5A -C ) . Treatment with either inhibitor of autophagy such as 3-methyladenine or wortmannin alone did not alter the phosphorylation of mTOR than Resveratrol induces autophagy via mTOR complex 2 that of normal (data not shown). Furthermore, treatment with 3-methyladenine or wortmannin along with resveratrol also inhibited the phosphorylation of mTOR at both serine 2448 and serine 2481 sites ( Figure 5A-C ) . mTOR assembles into two functionally distinct complexes, i.e. mTOR complex 1 (mTORC1) and mTORC2. Raptor, a component of mTORC1 is elevated in all resveratrol-treated samples irrespective of other treatments like rapamycin, wortmannin, or 3-methyladenine. To further analyse the role of mTORC1, we analysed the activation of p70s6 kinase (phosphorylation at Thr389), a direct down-stream target of mTORC1. p70s6 kinase was highly active during HR, and the activation of p70s6 kinase was dose dependently reduced by resveratrol treatment (Figure 5A and D) . Rapamycin abolished the p70s6 kinase activation, whereas the treatment with wortmannin or 3-methyladenine partially inhibited the p70s6 kinase activation ( Figure 5A and D) .
AMP-activated protein kinase (AMPK) serves as a general integrator of metabolic responses to changes in energy availability and is activated in response to elevations of the AMP/ATP ratio. 21 Low doses of resveratrol treatment extensively induced the activation of AMPK (phosphorylation at Thr172), compared with HR alone or high dose of resveratrol ( Figure 5A and E). Treatment with rapamycin, 3-methyladenine, or wortmannin attenuated low-dose resveratrol-induced AMPK activation ( Figure 5A and E).
Low-dose resveratrol treatment selectively induces mTOR complex 2 leading to autophagy induction
Rictor, the main component of mTORC2 was found to be induced only with low-dose resveratrol followed by HR ( Figure 6A) . However, HR alone or high-dose resveratrol did not induce Rictor ( Figure 6A) . Induction of autophagy with rapamycin and also inhibition of autophagy with wortmannin or 3-methyladenine abolished the low-dose resveratrol-induced Rictor expression ( Figure 6A) . Moreover, treatment with low-dose resveratrol without HR or treatment with rapamycin alone followed by HR did not induce Rictor expression (data not shown). These results strongly indicate that only low-dose resveratrol under HR condition induced the expression of Rictor, a component of mTORC2 known to activate cell survival via phosphorylation of Ser 473 and activation of Akt. In order to study whether the low-dose resveratrol-induced Rictor bind with mTOR, we immunoprecipitated the total cell lysate with mTOR antibody and the immunoprecipitate was analysed by western immunoblotting. The results showed that low-dose resveratrol-induced Rictor bound with mTOR in the total cell lysate ( Figure 6B) .
Recently, we have shown that the induction of autophagy by ischaemic preconditioning led to cell survival and that low-dose resveratrol is known to induce ischaemic-preconditioning like effects. 8, 14 On the basis of the above results, we hypothesized that the activation of Rictor-mediated mTORC2 survival pathway by low-dose resveratrol treatment under HR might be involved in the induction of autophagy. To test the above hypothesis, we transfected H9c2 cardiac myoblast cells with either Rictor siRNA or control siRNA as mentioned in Methods. The transfection efficiency in H9c2 cells was analysed by studying the expression of Rictor under low-dose resveratrol (1 mM) treatment followed by HR. Western immunoblotting analyses indicate that Rictor siRNA treatment considerably reduced the expression of Rictor in comparison to control siRNA-treated cells ( Figure 6C and D) . At the same time, the expression of LC3-II was significantly reduced in Rictor siRNA-treated cells compared with control siRNA-treated cells as shown by western immunoblotting and confocal immunofluorescence analysis ( Figure 6C , E, and F ). These results suggest that Rictor-mediated mTORC2 may participate in the induction of autophagy.
Discussion
The main findings of the current study are (i) low doses of resveratrol treatment induces autophagy in parallel to the enhanced cell survival and decreased cell death indicating the protection of cardiac cells against IR injury, (ii) low doses of resveratrol treatment specifically induces Rictor, a component of mTORC2, whereas mTORC1 is inhibited during the induction of autophagy. Autophagy is a self-clearing process to remove the damaged proteins or organelles, an alternate mechanism for proteasomal degradation, which can generate a survival signal, as in the case of myocardial ischaemia. 2, 23 Although autophagy was initially believed to be involved in a non-apoptotic form of programmed cell death, recent studies have changed this concept by demonstrating that autophagy can also cause cell survival. However, Matsui et al. 24 have
shown that in the case of myocardial ischaemic injury, autophagy causes cell survival, whereas the reperfusion injury causes cell death. In our own study, we found that myocardial ischaemic preconditioning induces autophagy for the protection of myocardium through the induction of BAG-1 survival protein. 8 As low-dose resveratrol-mediated survival signal is realized by its ability to induce pharmacological preconditioning, 13, 15 we tested the ability of resveratrol to induce autophagy in the myocardium. Our results show for the first time that low doses of resveratrol induce cardiac autophagy and generate a survival signal in H9c2 cardiac myoblast cells as well as in the myocardium, and the inhibition of autophagy diminished the resveratrol-mediated cardioprotection. Our results are consistent with our previous reports that resveratrol at low dose (2.5 mg/kg/ day) protects the myocardium from IR injury by reducing myocardial infarct size via the activation of Akt. 14 Treatment with rapamycin alone (data not shown) or treatment with rapamycin followed by low dose (1 mM) of resveratrol enhanced the autophagic puncta ( Figure 1D and E) and further enhanced the autophagosome formation ( Figure 2C ) measured by staining with monodansylcadaverine, which is shown to be specific for autophagosomes as described previously by Iwai-Kanai et al. 25 Further, treatment with 3-methyladenine or wortmannin, which inhibit the initial steps of autophagic process, attenuated the autophagic puncta and autophagosome formation ( Figure 1C -E) induced by low-dose resveratrol treatment. These results suggest that the entire process of autophagy is upregulated after low-dose of resveratrol treatment. Although high dose of resveratrol treatment in H9c2 cells decreased the autophagy, it did not alter the cell survival as observed with inhibitors of autophagy ( Figure 2 ). These in vitro results suggest that the resveratrol-mediated autophagy only partly contribute for the cell survival under the given set of experimental conditions. However, our in vivo data ( Figures 3 and 4) show that high dose of resveratrol decreased the autophagy and at the same time induced cell death. Further, it should be noted that even though cardiac IR alone markedly induced autophagy, HR alone in H9c2 cells did not. This discrepancy could be due to the difference between the ex vivo and in vitro experimental conditions. In order to study the mechanism of resveratrol-induced autophagy, we examined the activation of mTOR, a molecule known to be repressed during autophagic induction. TOR not only can act as an amino acid sensor, but also as a sensor of ATP. 26 mTOR assembles into two functionally distinct complexes: mTORC1 and mTORC2. mTORC1 comprises mTOR, Raptor, mLST8, and PRAS40, which represses mTORC1 activity. mTORC2 comprises mTOR, Rictor (rapamycin-insensitive companion of mTOR), SIN1, and mLST8. 27, 28 Rapamycin binds with FKBP12 and specifically inhibits mTORC1. 27 However, studies have shown that long-term treatment with rapamycin also inhibit the functions of mTORC2. 27, 29 Though inhibition of mTOR with rapamycin has been shown to induce autophagy in many cell types, 30 -33 in our study, rapamycin treatment did not induce further autophagy than that induced by low dose of resveratrol alone. These results indicate that resveratrol-mediated autophagy could also follow the same pathway as rapamycin through the inhibition of mTOR. However, our results show that mTOR was differentially regulated when autophagy was induced by low dose of resveratrol, i.e. phosphorylation of mTOR at serine 2448 was inhibited, whereas the phosphorylation of mTOR at serine 2481 was elevated. Our results are in accordance with a recent study, where resveratrol has been shown to inhibit oxidized LDL-induced PI3K/ Akt-mediated phosphorylation of mTOR (Ser2448) and its downstream molecule p70s6k in rabbit femoral smooth muscle cells. 34 However, p70s6k is needed for the entire process of autophagy, and it must be activated first for the maximal activation of autophagy. 35 Rictor, a component of mTORC2 was induced by low-dose resveratrol treatment, and it was found to be associated with mTOR shown by immunoprecipitation experiments. Rictor is primarily responsible for the phosphorylation of Akt on Ser 473 27 as observed in our study showing the induction of Rictor and simultaneous activation of Akt at Ser 473 (Figures 2 and 6 ). Akt phosphorylates a number of substrates involved in regulating cell survival, growth, proliferation, and metabolism. 36 As our results showed the positive correlation between the induction of Rictor, autophagy, and cell survival with low dose of resveratrol, we speculate whether mTORC2 could play any role in the induction of autophagy. To test this, we suppressed the expression of Rictor by Rictor siRNA treatment in cardiac myoblast cells, and this resulted in the suppression of autophagy induced by low dose of resveratrol followed by HR. In contrast, shRNA-mediated knockdown of Rictor induced autophagy in skeletal muscle cells. 37 Taken together, our results indicate that low-dose resveratrol-mediated cell survival is at least in part mediated through induction of autophagy, which may in part, depend on the activation of mTORC2 survival pathway. AMPK is a sensor of energy molecule ATP and is activated when the ratio of ATP/ADP is decreased. 38 -40 AMPK activation is shown to be dominantly inhibiting mTOR via two mechanisms: (i) by phosphorylation of TSC2 at Ser 1345 leading to the stimulation of GTPase activator protein (GAP) activity and (ii) by phosphorylation and inhibition of Raptor. Recently, it has been shown that glucose deprivation in cardiac cells and cardiac ischaemia activates AMPK leading to the activation of autophagy. 41, 42 Activated AMPK dominantly suppresses the effect of Akt on the activation of mTORC1, 43, 44 at the same time Akt activity negatively regulates AMPK phosphorylation. 45 Activation of Akt can activate mTORC1 in two ways: (i) by phosphorylation of TSC2 causing the inhibition of GAP domain of TSC2 leading to the activation of Rheb and mTORC1 and (ii) by phosphorylation of PRAS40 and relieving its inhibitory effect on mTORC1. On the basis of the above studies, we presume that low-dose resveratrol-mediated activation of AMPK could suppress the effect of Akt on the activation of mTORC1. In this study, rapamycin treatment inhibited the resveratrol-induced expression of Rictor, as rapamycin treatment can disrupt the interaction between Rictor and mTOR and can reduce the basal mTORC2 activity. 34 Prolonged rapamycin treatment increased the phosphorylation of Ser 473 despite a severe disruption of mTORC2 stability. 46 Inhibition of mTOR signalling by rapamycin has been shown to increase the Akt phosphorylation. 47 Also, in our study, rapamycin treatment increased the Ser 473 phosphorylation of Akt than low-dose resveratrol treatment alone. Thus, rapamycin treatment-induced activation of Akt through an unknown mechanism could probably involve in the cell survival seen in our present study as shown in Figure 3 . Beclin1/Atg6, the first mammalian protein described to mediate autophagy by forming a complex with Vps34, a class III PI3K, positively regulate autophagy via formation of autophagosomes and initiation of autophagy.
48 PI3K-III inhibitors such as 3-methyladenine, wortmannin, and LY294002 interfere with this pathway. 49 Resveratrol was shown to induce cell death in ovarian cancer cells through a mechanism distinct from apoptosis, 50 and induced Beclin-1-independent autophagy in breast cancer cells, 51 whereas Beclin-1-dependent autophagy was found in colorectal cancer cells. 17 To the best of our knowledge, this is the first study to show that resveratrol induces autophagy in the myocardium and in cardiac myoblast cells in Beclin-1-dependent manner. Inhibition of autophagy with 3-methyladenine and wortmannin, which is also known to inhibit both mTORC1 and mTORC2, 52, 53 inhibited resveratrol-mediated autophagy and abolished the cardioprotective abilities of resveratrol. Though the complex interaction and the positive and negative feedback regulation among PI3 kinase, Akt, mTOR, and AMPK are known to some extent, the exact mechanism through which 3-methyladenine and wortmannin causes the inactivation of mTOR and p70s6k is unclear.
In conclusion, our results indicate for the first time that low dose of resveratrol-induced cell survival is at least in part mediated through the induction of autophagy, which may, in part, depend on Rictormediated mTORC2 survival pathway.
Supplementary material
Supplementary Material is available at Cardiovascular Research online.
